Whether a tumor should be treated with chemotherapy or PD1 first should be judged according to the pathological type of the tumor, the patient’s physical condition, the tumor load and so on. Taking lung cancer as an example, if, for example, the expression of PD1 or PDL1 is high, and the patient’s physical condition is relatively good, PD1 or PDL1 inhibitors, such as pabolizumab, can be used in the first line. If the expression level of PD1 or PDL1 is low, the first-line use of PD1 or PDL1 inhibitors at this time will not be very effective, and need to be combined with chemotherapy or combined with anti-tumor angiogenesis drugs and other conditions in order to achieve better results. If there is a gene mutation, in the use of the gene mutation of the drug to use PD1 or PDL1 shift agents than the effect is better. In short, first chemotherapy or first on the PD1 inhibitor, according to the actual situation of comprehensive judgment.